WuXi Biologics announced that it has signed a license and research service agreement with Vertex Pharmaceuticals (VRTX) for a trispecific T-cell Engager for the treatment of B-cell mediated autoimmune diseases. Under the agreement, Vertex will have exclusive global rights to develop and commercialize an innovative trispecific TCE at the preclinical stage designed for the treatment of B-cell mediated autoimmune diseases. WuXi Biologics will receive an upfront payment and is eligible to receive development, regulatory, and sales milestone payments, as well as royalty payments. In addition, WuXi Biologics will provide Vertex with contract research and development services on novel next-generation TCEs.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Positive Risk-Reward on Emerging Renal Pipeline and Pove IgAN Phase 3 Catalyst Supports Buy Rating
- Vertex Pharmaceuticals assumed with Overweight from Equal Weight at Barclays
- Vertex Pharmaceuticals price target raised to $545 from $535 at UBS
- Vertex Pharmaceuticals price target raised to $530 from $475 at Evercore ISI
- Vertex Pharmaceuticals gets orphan status for membranous nephropathy treatment